Skip to main content

Advertisement

SpringerLink
Log in

BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

We report a patient with a metastatic relapse of clear cell sarcoma, whose tumor harbored BRAF V600E mutation. Standard chemotherapy with doxorubicin and ifosfamide failed to slow the disease progression. Subsequent administration of vemurafenib (960 mg twice a day) resulted in complete tumor response after 8 weeks of treatment. Literature data on the use of vemurafenib and dabrafenib in non-melanoma BRAF-mutated tumors are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig 1
Fig 2

Similar content being viewed by others

References

  1. Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ (2015) Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res 21:1028–1035

    Article  CAS  PubMed  Google Scholar 

  2. Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME (2015) Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab 100:E77–E81

    Article  CAS  PubMed  Google Scholar 

  3. Ali SM, He J, Carson W, Stephens PJ, Fiorillo J, Lipson D, Palmer GA, Ross JS, Miller VA, Sharman J (2014) Extended antitumor response of a BRAF V600E papillary thyroid carcinoma to vemurafenib. Case Rep Oncol 7:343–348

    Article  PubMed Central  PubMed  Google Scholar 

  4. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI (2013) Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 23:1277–1283

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O’Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379:1893–1901

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Marten KA, Gudena VK (2015) Use of Vemurafenib in Anaplastic Thyroid Carcinoma: A Case Report. Cancer Biol Ther (in press)

  7. Rosove MH, Peddi PF, Glaspy JA (2013) BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med 368:684–685

    Article  CAS  PubMed  Google Scholar 

  8. Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R (2015) BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 25:71–77

    Article  CAS  PubMed  Google Scholar 

  9. Gautschi O, Milia J, Cabarrou B, Bluthgen MV, Besse B, Smit EF, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Curioni-Fontecedro A, Huret B, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Mazières J (2015) Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J Thorac Oncol (in press).

  10. Karak FE, Assi T, Kourie HR, Rassy EE, Chebib R, Ghor M, Tabchi S (2015) BRAF(V600) mutant non-small-cell lung cancer resistant to Vemurafenib. Int J Clin Exp Pathol 8:3294–3298

    PubMed Central  PubMed  Google Scholar 

  11. Schmid S, Siano M, Joerger M, Rodriguez R, Müller J, Früh M (2015) Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. Lung Cancer 87:85–87

    Article  CAS  PubMed  Google Scholar 

  12. Robinson SD, O’Shaughnessy JA, Cowey CL, Konduri K (2014) BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer 85:326–330

    Article  PubMed  Google Scholar 

  13. Peters S, Michielin O, Zimmermann S (2013) Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol 31:e341–e344

    Article  PubMed  Google Scholar 

  14. Gautschi O, Peters S, Zoete V, Aebersold-Keller F, Strobel K, Schwizer B, Hirschmann A, Michielin O, Diebold J (2013) Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. Lung Cancer 82:365–367

    Article  PubMed  Google Scholar 

  15. Gautschi O, Pauli C, Strobel K, Hirschmann A, Printzen G, Aebi S, Diebold J (2012) A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 7:e23–e24

    Article  PubMed  Google Scholar 

  16. Haroche J, Cohen-Aubart F, Emile JF, Maksud P, Drier A, Tolédano D, Barete S, Charlotte F, Cluzel P, Donadieu J, Benameur N, Grenier PA, Besnard S, Ory JP, Lifermann F, Idbaih A, Granel B, Graffin B, Hervier B, Arnaud L, Amoura Z (2015) Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAFV600E-mutated erdheim-chester disease. J Clin Oncol 33:411–418

    Article  CAS  PubMed  Google Scholar 

  17. Tzoulis C, Schwarzlmüller T, Gjerde IO, Søfteland E, Neckelmann G, Biermann M, Haroche J, Straume O, Vintermyr OK (2015) Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. BMC Res Notes 8:171

    Article  PubMed Central  PubMed  Google Scholar 

  18. Gandolfi L, Adamo S, Pileri A, Broccoli A, Argnani L, Zinzani PL (2015) Multisystemic and multiresistant Langerhans cell histiocytosis: a case treated with BRAF inhibitor. J Natl Compr Cancer Netw 13:715–718

    Google Scholar 

  19. Bubolz AM, Weissinger SE, Stenzinger A, Arndt A, Steinestel K, Brüderlein S, Cario H, Lubatschofski A, Welke C, Anagnostopoulos I, Barth TF, Beer AJ, Möller P, Gottstein M, Viardot A, Lennerz JK (2014) Potential clinical implications of BRAF mutations in histiocytic proliferations. Oncotarget 5:4060–4070

    PubMed Central  PubMed  Google Scholar 

  20. Charles J, Beani JC, Fiandrino G, Busser B (2014) Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation. J Am Acad Dermatol 71:e97–e99

    Article  PubMed  Google Scholar 

  21. Euskirchen P, Haroche J, Emile JF, Buchert R, Vandersee S, Meisel A (2015) Complete remission of critical neurohistiocytosis by vemurafenib. Neurol Neuroimmunol Neuroinflamm 2:e78

    Article  PubMed Central  PubMed  Google Scholar 

  22. Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, Cluzel P, Drier A, Hervier B, Benameur N, Besnard S, Donadieu J, Amoura Z (2013) Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 121:1495–1500

    Article  CAS  PubMed  Google Scholar 

  23. Vergote V, Dierickx D, Janssens A, Verhoef G, Tousseyn T, Vandenberghe P, Wolter P, Delforge M (2014) Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib. Ann Hematol 93:2087–2089

    Article  CAS  PubMed  Google Scholar 

  24. Samuel J, Macip S, Dyer MJ (2014) Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med 370:286–288

    Article  CAS  PubMed  Google Scholar 

  25. Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R, Thyss A, Zenz T, Auberger P, Robert G (2013) Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica 98:e20–e22

    Article  PubMed Central  PubMed  Google Scholar 

  26. Bailleux C, Robert G, Ginet C, Re D, Thyss A, Sudaka I, Peyrottes I, Hofman P, Auberger P, Peyrade F (2014) Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib. Oncoscience 2:44–49

    PubMed Central  PubMed  Google Scholar 

  27. Follows GA, Sims H, Bloxham DM, Zenz T, Hopper MA, Liu H, Bench A, Wright P, Van’t Veer MB, Scott MA (2013) Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol 161:150–153

    Article  CAS  PubMed  Google Scholar 

  28. Munoz J, Schlette E, Kurzrock R (2013) Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol 31:e351–e352

    Article  PubMed  Google Scholar 

  29. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T (2012) BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 366:2038–2040

    Article  PubMed  Google Scholar 

  30. Dietrich S, Hüllein J, Hundemer M, Lehners N, Jethwa A, Capper D, Acker T, Garvalov BK, Andrulis M, Blume C, Schulte C, Mandel T, Meissner J, Fröhling S, von Kalle C, Glimm H, Ho AD, Zenz T (2013) Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol 31:e300–e303

    Article  CAS  PubMed  Google Scholar 

  31. Sharman JP, Chmielecki J, Morosini D, Palmer GA, Ross JS, Stephens PJ, Stafl J, Miller VA, Ali SM (2014) Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clin Lymphoma Myeloma Leuk 14:e161–e163

    Article  CAS  PubMed  Google Scholar 

  32. Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS (2013) Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov 3:862–869

    Article  CAS  PubMed  Google Scholar 

  33. Idbaih A, Mokhtari K, Emile JF, Galanaud D, Belaid H, de Bernard S, Benameur N, Barlog VC, Psimaras D, Donadieu J, Carpentier C, Martin-Duverneuil N, Haroche J, Feuvret L, Zahr N, Delattre JY, Hoang-Xuan K (2014) Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology 83:1478–1480

    Article  PubMed  Google Scholar 

  34. Yaeger R, Cercek A, O’Reilly EM, Reidy DL, Kemeny N, Wolinsky T, Capanu M, Gollub MJ, Rosen N, Berger MF, Lacouture ME, Vakiani E, Saltz LB (2015) Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res 21:1313–1320

    Article  CAS  PubMed  Google Scholar 

  35. Capalbo C, Marchetti P, Coppa A, Calogero A, Anastasi E, Buffone A, Belardinilli F, Gulino M, Frati P, Catalano C, Cortesi E, Giannini G, Gulino A (2014) Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report. Cancer Biol Ther 15:826–831

    Article  PubMed Central  PubMed  Google Scholar 

  36. Connolly K, Brungs D, Szeto E, Epstein RJ (2014) Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma. Curr Oncol 21:e151–e154

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Del Bufalo F, Carai A, Figà-Talamanca L, Pettorini B, Mallucci C, Giangaspero F, Antonelli M, Badiali M, Moi L, Bianco G, Cacchione A, Locatelli F, Ferretti E, Mastronuzzi A (2014) Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent. J Transl Med 12:356

    Article  PubMed Central  PubMed  Google Scholar 

  38. Bautista F, Paci A, Minard-Colin V, Dufour C, Grill J, Lacroix L, Varlet P, Valteau-Couanet D, Geoerger B (2014) Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer 61:1101–1103

    Article  CAS  PubMed  Google Scholar 

  39. Robinson GW, Orr BA, Gajjar A (2014) Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 14:258

    Article  PubMed Central  PubMed  Google Scholar 

  40. Skrypek M, Foreman N, Guillaume D, Moertel C (2014) Pilomyxoid astrocytoma treated successfully with vemurafenib. Pediatr Blood Cancer 61:2099–2100

    Article  PubMed  Google Scholar 

  41. Mordechai O, Postovsky S, Vlodavsky E, Eran A, Constantini S, Dotan E, Cagnano E, Weyl-Ben-Arush M (2015) Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: case report and review of the literature. Pediatr Hematol Oncol 32:207–211

    Article  PubMed  Google Scholar 

  42. Kaplan HG (2013) Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor. J Natl Compr Cancer Netw 11:1466–1470

    CAS  Google Scholar 

  43. Loaiza-Bonilla A, Clayton E, Furth E, O’Hara M, Morrissette J (2014) Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine. Ecancermedicalscience 8:479

    Article  PubMed Central  PubMed  Google Scholar 

  44. Kaye FJ, Ivey AM, Drane WE, Mendenhall WM, Allan RW (2014) Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst 107:378

    Article  PubMed  Google Scholar 

  45. Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, Blackman SC, Kurzrock R (2013) BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget 4:310–315

    PubMed Central  CAS  PubMed  Google Scholar 

  46. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483:100–103

    Article  CAS  PubMed  Google Scholar 

  47. Jones RL, Constantinidou A, Thway K, Ashley S, Scurr M, Al-Muderis O, Fisher C, Antonescu CR, D’Adamo DR, Keohan ML, Maki RG, Judson IR (2011) Chemotherapy in clear cell sarcoma. Med Oncol 28:859–863

    Article  PubMed  Google Scholar 

  48. Hocar O, Le Cesne A, Berissi S, Terrier P, Bonvalot S, Vanel D, Auperin A, Le Pechoux C, Bui B, Coindre JM, Robert C (2012) Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases. Dermatol Res Pract 2012:984096

    PubMed Central  CAS  PubMed  Google Scholar 

  49. Negri T, Brich S, Conca E, Bozzi F, Orsenigo M, Stacchiotti S, Alberghini M, Mauro V, Gronchi A, Dusio GF, Pelosi G, Picci P, Casali PG, Pierotti MA, Pilotti S (2012) Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma. Genes Chromosomes Cancer 51:111–26

    Article  CAS  PubMed  Google Scholar 

  50. Park BM, Jin SA, Choi YD, Shin SH, Jung ST, Lee JB, Lee SC, Yun SJ (2013) Two cases of clear cell sarcoma with different clinical and genetic features: cutaneous type with BRAF mutation and subcutaneous type with KIT mutation. Br J Dermatol 169:1346–1352

    Article  CAS  PubMed  Google Scholar 

  51. Pratilas CA, Xing F, Solit DB (2012) Targeting oncogenic BRAF in human cancer. Curr Top Microbiol Immunol 355:83–98

    PubMed Central  CAS  PubMed  Google Scholar 

  52. Ledford H (2014) Projects seek hidden effects of cancer drugs. Nature 516:21–22

    Article  CAS  PubMed  Google Scholar 

  53. Yang L, Chen Y, Cui T, Knösel T, Zhang Q, Geier C, Katenkamp D, Petersen I (2012) Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma. Hum Pathol 43:1463–1470

    Article  CAS  PubMed  Google Scholar 

  54. Yatabe Y, Pao W, Jett JR (2012) Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. J Thorac Oncol 7:775–776

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work has been supported by the Russian Scientific Fund (grant number 14-15-00528). We are grateful to Dr. Hannah West (University of Cambridge School of Clinical Medicine, UK) for a critical reading of this manuscript.

Conflict of interest

The author(s) declare that they have no conflict of interests.

Author information

Authors and Affiliations

  1. Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, 197758, St.-Petersburg, Russia

    Svetlana A. Protsenko, Anna I. Semionova, Yuri I. Komarov, Svetlana N. Aleksakhina, Alexandr O. Ivantsov & Evgeny N. Imyanitov

  2. St.-Petersburg Pediatric Medical University, St.-Petersburg, 194100, Russia

    Aglaya G. Iyevleva & Evgeny N. Imyanitov

  3. I.I. Mechnikov North-Western Medical University, St. Petersburg, 191015, Russia

    Evgeny N. Imyanitov

  4. St. Petersburg State University, St. Petersburg, 199034, Russia

    Evgeny N. Imyanitov

Authors
  1. Svetlana A. Protsenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna I. Semionova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuri I. Komarov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Svetlana N. Aleksakhina
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexandr O. Ivantsov
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aglaya G. Iyevleva
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Evgeny N. Imyanitov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Evgeny N. Imyanitov.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Protsenko, S.A., Semionova, A.I., Komarov, Y.I. et al. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment. Invest New Drugs 33, 1136–1143 (2015). https://doi.org/10.1007/s10637-015-0280-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-015-0280-0

Keywords

Search

Navigation